| Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases BJ Boyarsky, JA Ruddy, CM Connolly, MT Ou, WA Werbel, ... Annals of the rheumatic diseases 80 (8), 1098-1099, 2021 | 185 | 2021 |
| High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases JA Ruddy, CM Connolly, BJ Boyarsky, WA Werbel, L Christopher-Stine, ... Annals of the rheumatic diseases 80 (10), 1351-1352, 2021 | 126 | 2021 |
| Disease flare and reactogenicity in patients with rheumatic and musculoskeletal diseases following two‐dose SARS–CoV‐2 messenger RNA vaccination CM Connolly, JA Ruddy, BJ Boyarsky, I Barbur, WA Werbel, D Geetha, ... Arthritis & Rheumatology 74 (1), 28-32, 2022 | 114 | 2022 |
| Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases CM Connolly, JA Ruddy, BJ Boyarsky, RK Avery, WA Werbel, DL Segev, ... Annals of the rheumatic diseases 80 (8), 1100-1101, 2021 | 62 | 2021 |
| Absence of humoral response after two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases: a case series CM Connolly, BJ Boyarsky, JA Ruddy, WA Werbel, L Christopher-Stine, ... Annals of internal medicine 174 (9), 1332-1334, 2021 | 56 | 2021 |
| Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series CM Connolly, TPY Chiang, BJ Boyarsky, JA Ruddy, M Teles, JL Alejo, ... Annals of the rheumatic diseases 81 (2), 293-295, 2022 | 53 | 2022 |
| Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series CM Connolly, M Teles, S Frey, BJ Boyarsky, JL Alejo, WA Werbel, ... Annals of the rheumatic diseases 81 (2), 291-293, 2022 | 48 | 2022 |
| Immune-related adverse events: a case-based approach C Connolly, K Bambhania, J Naidoo Frontiers in oncology 9, 530, 2019 | 41 | 2019 |
| Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases TPY Chiang, CM Connolly, JA Ruddy, BJ Boyarsky, JL Alejo, WA Werbel, ... Annals of the rheumatic diseases 80 (10), 1365-1366, 2021 | 30 | 2021 |
| Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease S Frey, TPY Chiang, CM Connolly, M Teles, JL Alejo, BJ Boyarsky, ... The Lancet Rheumatology 4 (4), e241-e243, 2022 | 26 | 2022 |
| Attenuated response to fourth dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series M Teles, CM Connolly, S Frey, TPY Chiang, JJ Alejo, BJ Boyarsky, ... Annals of the rheumatic diseases 81 (5), 738-740, 2022 | 24 | 2022 |
| Antibody response six months after SARS-CoV-2 mRNA vaccination in patients with inflammatory bowel disease S Frey, R Chowdhury, CM Connolly, WA Werbel, DL Segev, AM Parian, ... Clinical Gastroenterology and Hepatology 20 (7), 1609-1612. e1, 2022 | 22 | 2022 |
| Correspondence on “SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response” by Bonelli et al CM Connolly, D Koenig, SN Ravi, A Azar, S Kant, M Dalal, J Duchen, ... Annals of the rheumatic diseases 80 (10), e164-e164, 2021 | 18 | 2021 |
| Comparison of SARS-CoV-2 antibody response after 2-dose mRNA-1273 vs BNT162b2 vaccines in incrementally immunosuppressed patients J Mitchell, CM Connolly, TPY Chiang, JL Alejo, WA Werbel, DL Segev, ... JAMA Network Open 5 (5), e2211897-e2211897, 2022 | 16 | 2022 |
| Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination S Frey, CM Connolly, TPY Chiang, M Teles, JL Alejo, BJ Boyarsky, ... The Lancet Rheumatology 3 (11), e753-e754, 2021 | 13 | 2021 |
| Effects of ischemic preconditioning on abdominal aortic aneurysm repair: a systematic review and meta-analysis S De Freitas, CW Hicks, R Mouton, S Garcia, D Healy, C Connolly, ... Journal of Surgical Research 235, 340-349, 2019 | 11 | 2019 |
| Factors associated with poor antibody response to third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases CM Connolly, TPY Chiang, M Teles, S Frey, JL Alejo, A Massie, AA Shah, ... The Lancet Rheumatology 4 (6), e382-e384, 2022 | 10 | 2022 |
| Possible future avenues for myositis therapeutics: DM, IMNM and IBM CM Connolly, L Plomp, JJ Paik, Y Allenbach Best Practice & Research Clinical Rheumatology 36 (2), 101762, 2022 | 9 | 2022 |
| Antibody response 3 months after 2-dose SARS-CoV-2 mRNA vaccination in patients with inflammatory bowel disease E Tsipotis, S Frey, C Connolly, WA Werbel, R Chowdhury, ... Official journal of the American College of Gastroenterology| ACG 117 (5 …, 2022 | 9 | 2022 |
| Anakinra for recurrent fevers in systemic lupus erythematosus E Dein, A Ingolia, C Connolly, R Manno, H Timlin Cureus 10 (12), 2018 | 9 | 2018 |
